Nursing Cancer Chemotherapy Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of EGFR: Lapatinib (Tykerb, Tyverb)
Click on the correct answer.
Vandetanib (Capreisa):
Classified as a "targeted" therapy.
Primarily useful in treating non-small cell lung cancer (NSCLC)
Both
Neither
Vandetanib clinical application(s):
Unresectable, locally advanced medullary thyroid cancer treatment
Metastatic medullary thyroid cancer treatment
Both
Neither
Anticancer activity associated with vandetanib involve/involves:
Inhibition of EGFR
Inhibition of vascular endothelial growth factor receptor (VEGFR)
Both
Neither
Vandetanib administration inhibits Src, a non-receptor tyrosine kinase which exhibits dysregulation in cancer.
True
False
Vandetanib and RET (an abbreviation for "rearranged during transfection):
Vandetanib inhibits the RET proto-oncogene which encodes for a receptor tyrosine kinase.
RET exhibiting gain of function mutations Appear involved in several human cancers including medullary thyroid cancer, multiple endocrine neoplasias (type 2a and type 2b), pheochromocytoma and parathyroid hyperplasia.
Both
Neither
Vandetanib Is associated with life-threatening adverse effects which includes sudden cardiac death.
True
False
Vandetanib pharmacokinetic/pharmacodynamics:
Slow absorption
Mainly metabolized by the liver cytochrome P450 drug metabolizing system mainly utilizing the CYP3A4 isoform.
Congenital long QT syndrome is a contraindication for vandetanib administration.
True
False
Vandetanib may be harmful to the fetus. Accordingly, females who may bear children should be advised to avoid pregnancy. Effective contraception should be used for at least four months following the last vandetanib dose.
True
False
Adverse reactions associated with vandetanib administration involve many organ systems including the cardiovascular system, CNS, dermatologic and others
